BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 2446807)

  • 1. Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen.
    Rock RC; Chan DW; Bruzek D; Waldron C; Oesterling J; Walsh P
    Clin Chem; 1987 Dec; 33(12):2257-61. PubMed ID: 2446807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
    Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
    Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study on the diagnostic value of prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) in patients with carcinoma of the prostate gland.
    van Dieijen-Visser MP; Delaere KP; Gijzen AH; Brombacher PJ
    Clin Chim Acta; 1988 May; 174(2):131-40. PubMed ID: 2454767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is prostate-specific antigen the most useful marker for screening in prostate cancer?
    Delaere KP; Van Dieijen-Visser MP; Gijzen AH; Brombacher PJ
    Am J Clin Oncol; 1988; 11 Suppl 2():S65-7. PubMed ID: 2468276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared.
    Chan DW; Bruzek DJ; Oesterling JE; Rock RC; Walsh PC
    Clin Chem; 1987 Oct; 33(10):1916-20. PubMed ID: 2444361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of prostate-specific antigen in untreated prostatic carcinoma.
    Oosterom R; Bogdanowicz J; Schröder FH
    Eur Urol; 1989; 16(4):253-7. PubMed ID: 2475344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma].
    Bentvelsen FM; Bogdanowicz JF; Oosterom R; Schröder FH
    Ned Tijdschr Geneeskd; 1990 Aug; 134(33):1596-600. PubMed ID: 1697651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen (PSA) in the management of 500 prostatic patients.
    Guillet J; Role C; Duc AT; François H
    Am J Clin Oncol; 1988; 11 Suppl 2():S61-2. PubMed ID: 2468274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens.
    Gallee MP; Visser-de Jong E; van der Korput JA; van der Kwast TH; ten Kate FJ; Schroeder FH; Trapman J
    Urol Res; 1990; 18(3):181-7. PubMed ID: 1697709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
    Buamah PK; Johnson P; Skillen AW
    Br J Urol; 1988 Dec; 62(6):581-3. PubMed ID: 2464396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical and physiological characteristics of prostate-specific antigen and prostatic acid phosphatase in serum compared.
    Schifman RB; Ahmann FR; Elvick A; Ahmann M; Coulis K; Brawer MK
    Clin Chem; 1987 Nov; 33(11):2086-8. PubMed ID: 2445507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic value of urinary transferrin compared to serum prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer.
    van Dieijen-Visser MP; Hendriks MW; Delaere KP; Gijzen AH; Brombacher PJ
    Clin Chim Acta; 1988 Sep; 177(1):77-80. PubMed ID: 2460272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate.
    Dupont A; Cusan L; Gomez JL; Thibeault MM; Tremblay M; Labrie F
    J Urol; 1991 Oct; 146(4):1064-7; discussion 1067-8. PubMed ID: 1716697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of PSA and PAP in patients with or without prostatic cancer.
    Caty A; Gosselin P; Cazin JL; Dehaut JM; Adenis L
    Am J Clin Oncol; 1988; 11 Suppl 2():S63-4. PubMed ID: 2468275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with prostate-specific antigen in prostatic carcinoma.
    Romics I; Bach D
    Int Urol Nephrol; 1991; 23(5):465-72. PubMed ID: 1718923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Discrepancy between the serum levels of gamma seminoprotein and prostate-specific antigen in patients with prostatic neoplasms. Both true or either untrue].
    Fujino A; Mukai N; Kawakami T; Yokoyama E; Mashimo S; Endo T; Ishibashi A; Koshiba K; Aoki Y; Itoh H
    Nihon Hinyokika Gakkai Zasshi; 1991 Apr; 82(4):541-50. PubMed ID: 1711133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen in management of prostatic carcinoma.
    Brawer MK; Lange PH
    Urology; 1989 May; 33(5 Suppl):11-6. PubMed ID: 2469244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of prostate-specific antigen in serum by immunoradiometric assay.
    Lindstedt G; Jacobsson A; Lundberg PA; Hedelin H; Pettersson S; Unsgaard B
    Clin Chem; 1990 Jan; 36(1):53-8. PubMed ID: 1688745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
    Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
    N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate specific antigen--a screening test for prostatic cancer?
    Powell CS; Fielding AM; Rosser K; Ames AC; Vaughton KC
    Br J Urol; 1989 Nov; 64(5):504-6. PubMed ID: 2482112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.